Ross Quoted in Business Insurance About Insurance M&A Activity Amid Pandemic
12 November 2020
Partner Anne Ross was quoted in the Business Insurance article, “M&A deals continue for brokers; on the horizon for insurers: Panel,” about mergers and acquisitions activity in the insurance industry during the COVID-10 pandemic.
“The pandemic has really accelerated the importance of the technology platform and the ability to work with distribution channels with technology,” Ross said. She was speaking about the activity
at an online panel sponsored by S&P Global Market Intelligence, a division of S&P Global Ratings Inc..
Ross also noted that insurers are facing declining investment income, and some are also still dealing with business interruption insurance litigation.
“The pandemic has really accelerated the importance of the technology platform and the ability to work with distribution channels with technology,” Ross said. She was speaking about the activity
at an online panel sponsored by S&P Global Market Intelligence, a division of S&P Global Ratings Inc..
Ross also noted that insurers are facing declining investment income, and some are also still dealing with business interruption insurance litigation.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”